- Wisp debuts its first-ever exclusive over-the-counter
weight-loss supplement, designed to promote women's metabolic
health.
- Wisp introduces personalized, online consultations with access
to four weight care solutions, including GLP-1 medications, to
support women struggling with hormonal conditions such as
perimenopause, menopause, Polycystic Ovary Syndrome (PCOS), and
endometriosis.
- With over 1.2 million patients, Wisp Now Also Bolsters its
Menopause Solutions, Empowering Women Through All Major Stages of
Their Healthcare Journey
VANCOUVER, BC and TORONTO, Oct. 17,
2024 /CNW/ - WELL Health Technologies Corp. (TSX:
WELL) (OTCQX: WHTCF) ("WELL" or the "Company"), a
digital healthcare company focused on improving health outcomes
through technology and empowering healthcare providers globally, is
pleased to announce the launch of a new weight care vertical by its
majority-owned subsidiary, Wisp, the largest dedicated women's
telehealth provider in the U.S. With Wisp now serving over 1.2
million patients, this expansion represents a pivotal step forward
in addressing critical health needs related to hormonal imbalances
and weight management for women.
Through this launch, Wisp introduces personalized, online
consultations with access to four weight care solutions, including
GLP-1 medications, to support women struggling with hormonal
conditions such as perimenopause, menopause, Polycystic Ovary
Syndrome (PCOS), and endometriosis. Additionally, Wisp debuts its
first-ever exclusive over-the-counter weight care capsules,
designed to promote women's metabolic health.
"Wisp is committed to providing sustainable support for women's
weight loss journeys, addressing a critical yet overlooked aspect
of women's health," said Monica
Cepak, CEO of Wisp. "As the dialogue around obesity evolves,
we recognize that underlying conditions — especially hormonal
imbalances linked to perimenopause and menopause — remain
under-researched, underdiagnosed, and undertreated. With these new
offerings, we're proud to continue expanding access to
comprehensive care, offering tailored solutions for every woman and
every condition at every price point."
"The launch of Wisp's weight care vertical taps into the
transformative potential of GLP-1 therapies," said Hamed Shahbazi, Founder and CEO of WELL. "These
treatments are reshaping healthcare by addressing weight management
while enhancing metabolic health and alleviating hormonal
challenges. For women experiencing conditions like PCOS,
perimenopause, and menopause, GLP-1s open doors to improved health
outcomes and a better quality of life. By integrating these
therapies into Wisp's offerings, we are delivering personalized
care at scale and positioning ourselves at the leading edge of
women's healthcare innovation."
Starting today, Wisp offers GLP-1 medications and supplements
via pharmacy pickup or free, discreet delivery, following an online
health consultation with a licensed provider. The program also
includes educational content and monthly check-ins to ensure
effective support throughout the patient's journey. Wisp's weight
care program includes:
- Semaglutide (FDA-approved Wegovy®):
Subcutaneous injectable medication
- Compounded Semaglutide: Subcutaneous and sublingual
options
- Metabolic Support & GLP-1 Boost Capsules: Natural
supplement with key ingredients such as:
-
- Eriomin®: Supports insulin function and
healthy glucose levels
- Actiz!ng™ (Black Ginger Extract): Boosts
calorie burn and reduces abdominal fat
- GlucoVantage® Dihydroberberine: Aids in body
composition and blood sugar management
- PoZibio™ (Lactobacillus paracasei): Promotes gut health
and metabolic function
In tandem with this launch, Wisp strengthens its menopause
solutions, addressing the healthcare gap for the over 2 million
women experiencing menopause annually. New offerings include
Estriol Face Cream and hormone replacement therapies such as
Transdermal Estradiol Patches, Oral Micronized Progesterone
Capsules, and Provera Tablets.
These initiatives reflect Wisp's commitment to providing
affordable, inclusive healthcare for women, complementing WELL's
strategic vision of expanding access to high-quality care. Wisp's
upcoming plans also include new at-home diagnostics and treatment
options in STI, fertility, menopause, and weight care categories,
further solidifying its leadership in digital women's health.
For more information about Wisp, visit www.hellowisp.com.
About WELL Health Technologies Corp.
WELL's mission is to tech-enable healthcare providers. We do
this by developing the best technologies, services, and support
available, which ensures healthcare providers are empowered to
positively impact patient outcomes. WELL's comprehensive healthcare
and digital platform includes extensive front and back-office
management software applications that help physicians run and
secure their practices. WELL's solutions enable more than 37,000
healthcare providers between the US and Canada and power the largest owned and
operated healthcare ecosystem in Canada with more than 180 clinics supporting
primary care, specialized care, and diagnostic services. In
the United States WELL's solutions
are focused on specialized markets such as the gastrointestinal
market, women's health, primary care, and mental health. WELL is
publicly traded on the Toronto Stock Exchange under the symbol
"WELL" and on the OTC Exchange under the symbol "WHTCF". To learn
more about WELL, please visit: www.well.company.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/wells-subsidiary-wisp-launches-comprehensive-weight-care-vertical-inclusive-of-glp-1-medications-to-support-women-struggling-with-hormonal-imbalances-302278979.html
SOURCE WELL Health Technologies Corp.